Under the agreement, Grifols will develop, manufacture and supply commercial quantities of Cadence’s OFIRMEV (acetaminophen) injection in flexible plastic bags.
OFIRMEV (acetaminophen) injection, which is available in1000 mg / 100 mL, 10 mg / mL dosage strengths for intravenous use, is indicated for the management of mild to moderate pain, moderate to severe pain with adjunctive opioid analgesics, and fever.
Cadence Pharmaceuticals president and CEO Ted Schroeder said, "As a result of our new collaboration with Grifols, we anticipate that by the second half of 2014, we will be able to offer our customers the option of purchasing OFIRMEV in flexible IV bags."
Laboratorios Grifols president Jose Antonio Garcia said, "The agreement with Cadence will further enhance Grifols’ third-party drug manufacturing activities, contributing to the geographical diversification of the division, and helping to maximize the use of the manufacturing facilities at Parets del Valles (Barcelona, Spain)."
In addition, Cadence announced that it has extended its supply arrangement for OFIRMEV in glass vials with Lawrence Laboratories, a member of the Bristol Myers Squibb group of companies, through 31 December 2018 , while terminated development and supply agreement with Baxter Healthcare.